H. Lee Moffitt Cancer Center and Research Institute: Carcinoma, Non-Small-Cell Lung trials

The registry lists 24 Carcinoma, Non-Small-Cell Lung studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 2 are open to participants now and 12 have results posted.

Early Phase 1 1Phase 1 12Phase 2 12Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCRecruitingNCT06745882Phase 2
• Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCRecruitingNCT05681780Phase 1
• Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03663166Phase 1/2Results posted
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerActive, not recruitingNCT03377023Phase 1/2Results posted
• Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerCompletedNCT03215810Phase 1Results posted
• Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT02638090Phase 1/2Results posted
• Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)CompletedNCT01999985Phase 1Results posted
• Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target ModulationTerminatedNCT00858403Phase 2Results posted
• Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)CompletedNCT00673738Phase 2Results posted
• Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLCCompletedNCT00499109Phase 3Results posted
• Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung CancerTerminatedNCT00351039Phase 1/2Results posted
• Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung CancerCompletedNCT00231465Phase 2Results posted
• Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.CompletedNCT00226577Phase 2Results posted
• The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung CancerCompletedNCT00215930Phase 2Results posted
• High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)Active, not recruitingNCT06337552Not applicable
• Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)SuspendedNCT06219174Phase 1/2
• Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLCCompletedNCT05873439Early Phase 1
• Immunonutrition to Reduce Toxicities in Non-Small Cell Lung CancerWithdrawnNCT03628144Phase 2
• Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCActive, not recruitingNCT03611738Phase 1
• Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLCCompletedNCT03177291Phase 1
• Pilot Study of Regional Lung VentilationCompletedNCT03077113Not applicable
• Oncology Research Information Exchange Network (ORIEN) Lung Cancer StudyCompletedNCT02803333
• A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationCompletedNCT01859026Phase 1
• Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)CompletedNCT00444015Phase 1